Ascorbic Acid Treatment in CMT1A Trial (AATIC) (AATIC)
Charcot-Marie-Tooth Disease, Hereditary Motor and Sensory Neuropathies
About this trial
This is an interventional treatment trial for Charcot-Marie-Tooth Disease focused on measuring Charcot-Marie-Tooth Disease, Hereditary Motor and Sensory Neuropathies, Ascorbic Acid, Vitamin C
Eligibility Criteria
Inclusion Criteria: DNA-proven CMT1A patients Age 12-25 years CMT 1A patients with symptomatology defined as muscle weakness in at least foot dorsiflexion Exclusion Criteria: Due to possible influence on severity of the neuropathy: Known other disease that may cause a neuropathy, that may decrease mobility, or that may lead to severe disability or death in a short time Medication that may cause a neuropathy Chronic alcohol abuse Due to study medication (ascorbic acid): Regular use of vitamin C Clinical or echographic signs of nephrolithiasis Reduced glomerular filtration rate Iron overload No regular dental control at the dentist Pregnancy or active pregnancy wish for women Due to study design and primary outcome: Not signing the informed consent Psychiatric co-morbidity which may influence compliance Not being comfortable during nerve conduction studies of the median nerve A too small CMAP amplitude of the abductor pollicis brevis muscle for a proper determination of the nerve conduction velocity of the median nerve
Sites / Locations
- Department of Neurology Academic Medical Center University of Amsterdam
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Ascorbic acid
Placebo